About Callidus Biopharma
Callidus Biopharma is a company based in Doylestown (United States) founded in 2010 was acquired by Amicus Therapeutics in November 2013.. Callidus Biopharma has raised $4.61 million across 1 funding round from investors including Amicus Therapeutics. Callidus Biopharma operates in a competitive market with competitors including Rhythm Pharmaceuticals, MannKind Corp, NGM Biopharmaceuticals, Corcept and ViaCyte, among others.
- Headquarter Doylestown, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Callidus Biopharma, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$4.61 M (USD)
in 1 rounds
-
Latest Funding Round
$4.61 M (USD), Series A
Apr 12, 2013
- Investors
-
Employee Count
Employee Count
-
Acquired by
Amicus Therapeutics
(Nov 20, 2013)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Callidus Biopharma
Callidus Biopharma has successfully raised a total of $4.61M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.61 million completed in April 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $4.6M
-
First Round
First Round
(12 Apr 2013)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2013 | Amount | Series A - Callidus Biopharma | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Callidus Biopharma
Callidus Biopharma has secured backing from 1 investor. Prominent investors backing the company include Amicus Therapeutics. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer of therapies for rare and orphan diseases
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Callidus Biopharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Callidus Biopharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Callidus Biopharma Comparisons
Competitors of Callidus Biopharma
Callidus Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Rhythm Pharmaceuticals, MannKind Corp, NGM Biopharmaceuticals, Corcept and ViaCyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Developer of small-molecule drugs
|
|
| domain | founded_year | HQ Location |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| domain | founded_year | HQ Location |
Developer of cortisol modulators for the treatment of various diseases
|
|
| domain | founded_year | HQ Location |
Cell therapy for diabetes is developed from stem cells.
|
|
| domain | founded_year | HQ Location |
Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Callidus Biopharma
Frequently Asked Questions about Callidus Biopharma
When was Callidus Biopharma founded?
Callidus Biopharma was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Where is Callidus Biopharma located?
Callidus Biopharma is headquartered in Doylestown, United States. It is registered at Doylestown, Pennsylvania, United States.
Is Callidus Biopharma a funded company?
Callidus Biopharma is a funded company, having raised a total of $4.61M across 1 funding round to date. The company's 1st funding round was a Series A of $4.61M, raised on Apr 12, 2013.
What does Callidus Biopharma do?
Callidus Biopharma is a drug discovery company focused on best-in-class enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs). Callidus novel technology platform is based on attaching a form of the naturally occurring Insulin-like Growth Factor (IGF-2) to enhance the targeting of therapeutic enzymes to the relevant cells in the body. The companys therapeutics offer the potential to significantly reduce the amount of drug that needs to be infused, which translates to patient and medical benefits of better efficacy, shorter infusion times, reduced immunogenicity, and greater convenience. Our lead program is for Pompe Disease but we are also applying our IGF2 technology to other LSDs to improve drug targeting and efficacy. We have also created a more stable enzyme which has the potential to be a superior ERT for Gaucher Disease.
Who are the top competitors of Callidus Biopharma?
Callidus Biopharma's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept.
Who are Callidus Biopharma's investors?
Callidus Biopharma has 1 investor. Key investors include Amicus Therapeutics.